Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 100.
THEOCLEAR L.A.-130 vs THEOCLEAR-100
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Treatment of asthma (FDA-approved)Treatment of chronic obstructive pulmonary disease (COPD) (off-label)
Treatment of asthmaChronic obstructive pulmonary disease (COPD)
130 mg orally every 12 hours; extended-release tablet.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4 (major); also N-demethylation and oxidation. Exhibits non-linear pharmacokinetics.
Hepatic via CYP1A2 and CYP3A4; also undergoes N-demethylation and oxidation.
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Approximately 40% bound to plasma proteins, primarily albumin. Binding is reversible and independent of concentration within therapeutic range.
Approximately 40% bound to albumin in plasma.
Vd of 0.3-0.7 L/kg (average 0.5 L/kg) approximates total body water. This indicates extensive distribution into tissues, with higher concentrations in tissues than plasma.
Apparent volume of distribution is 0.3-0.65 L/kg, reflecting distribution throughout total body water.
Oral bioavailability of the sustained-release formulation approaches 100% due to complete absorption. However, food can affect absorption rate; with Theoclear L.A.-130, high-fat meals may increase peak concentration and rate of absorption.
Oral immediate-release: 96-100%. Oral sustained-release: 90-100% relative to immediate-release. Rectal: 80-90%.
No specific adjustment required; monitor serum concentrations and adjust dose based on clinical response and trough levels.
No specific dose adjustment required for renal impairment; monitor serum levels due to altered pharmacokinetics in severe renal failure (GFR <10 mL/min).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels closely.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated.
Not recommended for children under 6 years; for children 6-12 years: 130 mg once daily initially, titrate based on weight and serum levels (target 5-15 mcg/mL).
Initial: 5 mg/kg/day orally divided every 6 hours; titrate based on serum levels. Maximum: 16 mg/kg/day (max 400 mg/day) for children >1 year.
Initiate at lower end of dosing range (130 mg once daily) and titrate slowly; monitor for toxicity due to reduced clearance.
Start at lower end of dosing (e.g., 100 mg every 8-12 hours) due to decreased clearance; monitor serum concentrations closely; target 5-10 mcg/mL.
No FDA black box warning.
No FDA black box warning.
["Risk of seizures and arrhythmias at high serum levels (therapeutic range 10-20 mcg/mL)","Monitor serum theophylline levels regularly","Use caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders","May exacerbate arrhythmias; ECG monitoring recommended","Drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin)"]
Monitor serum levels due to narrow therapeutic index; risk of toxicity (seizures, arrhythmias); use caution in hepatic impairment, heart failure, elderly, and with concurrent medications that alter metabolism.
["Hypersensitivity to theophylline or any component","Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)","Uncontrolled seizure disorder","Active peptic ulcer disease"]
Hypersensitivity to theophylline; porphyria.
Data Pending Review
Data Pending Review
Avoid high-fat meals which may alter absorption of sustained-release tablets. Limit caffeine intake from coffee, tea, cola, and chocolate. Charcoal-grilled foods may increase clearance. No specific dietary restrictions beyond caffeine moderation; maintain consistent diet to avoid fluctuations in drug levels.
High-fat meals may slow absorption of some formulations; charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) can increase theophylline clearance. Consistent dietary habits are advised to avoid fluctuations in serum levels.
Theophylline (THEOCLEAR L.A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above baseline. Third trimester use may cause neonatal irritability, tachycardia, and vomiting due to transplacental transfer. Risk of fetal respiratory depression is low at therapeutic maternal levels.
FDA Pregnancy Category C. First trimester: limited data suggest possible increased risk of congenital malformations; second and third trimesters: associated with fetal tachycardia, jitteriness, and respiratory distress; avoid use near term due to risk of neonatal theophylline toxicity.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose. Adverse effects in nursing infants (irritability, sleep disturbance) have been reported. Caution advised; monitor infant for toxicity.
Theophylline excreted into breast milk with infant serum levels approximately 10% of maternal; M/P ratio ~0.7. Cautious use only if benefits outweigh risks; monitor infant for irritability and poor feeding.
Pregnancy decreases theophylline clearance (especially third trimester due to decreased hepatic metabolism) and increases volume of distribution. Dose requirements may decrease by 20-30% in later pregnancy. Monitor serum levels and adjust dose to maintain therapeutic range (5-15 mcg/mL). Postpartum clearance returns rapidly (within 2 weeks); dose reduction may be needed to avoid toxicity.
Increased clearance in second and third trimesters may require dose increases of 30-50%; monitor levels and adjust to maintain therapeutic range; postpartum dose reduction may be needed due to clearance returning to non-pregnant levels.
Category C
Category C
Theophylline has a narrow therapeutic index (10-20 mcg/mL). Levels >20 mcg/mL increase toxicity risk. Immunoassay cross-reactivity with caffeine and other xanthines may falsely elevate levels. Adjust dose in heart failure, liver disease, and for drug interactions with cimetidine, fluoroquinolones, and macrolides. Smoking induces metabolism requiring dose increase. Sustained-release formulations should not be crushed or chewed.
Theophylline has a narrow therapeutic index (5-15 mcg/mL). Monitor serum levels due to variable metabolism; CYP1A2 and CYP3A4 inducers (e.g., smoking, rifampin) decrease levels, while inhibitors (e.g., cimetidine, fluoroquinolones) increase toxicity. Use with caution in heart failure, hepatic impairment, and elderly. Tachyphylaxis may occur with prolonged use.
Do not crush or chew sustained-release tablets; swallow whole.Take exactly as prescribed; do not double doses if missed.Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.Contact your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.Inform all healthcare providers you are taking this medication.Do not stop suddenly without consulting your doctor.
Take exactly as prescribed; do not double doses.Report symptoms of toxicity: nausea, vomiting, insomnia, irritability, palpitations, seizures.Avoid smoking or sudden smoking cessation as it alters drug levels.Limit caffeine intake (coffee, tea, cola, chocolate) to avoid additive stimulant effects.Do not crush or chew extended-release tablets; swallow whole.